Marc Voigt Acquires 29,500 Shares of Immutep Limited (ASX:IMM) Stock

Immutep Limited (ASX:IMM) insider Marc Voigt acquired 29,500 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were bought at an average price of A$0.34 ($0.23) per share, for a total transaction of A$10,030.00 ($6,869.86).

Immutep Price Performance

The company has a debt-to-equity ratio of 0.84, a current ratio of 18.25 and a quick ratio of 13.78.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.